Second Circuit Revives Regeneron’s Antitrust Action Against Novartis
- March 22, 2024
The Second Circuit reversed March 18 the dismissal of Regeneron Pharmaceuticals, Inc.’s antitrust and tortious interference of contract claims against rival Novartis Pharmaceuticals Corp. involving prescription medications used to treat overproduction of a protein that can lead to ophthalmic diseases.
ARTICLE TAGS
You must be logged in to access this content.